Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

Siraj M. Ali, R. Kathy Alpaugh, Jamie K. Buell, Philip J. Stephens, Jian Qin Yu, Hong Wu, Christine N. Hiemstra, Vincent A. Miller, Doron Lipson, Gary A. Palmer, Jeffrey S. Ross, Massimo Cristofanilli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint Dive into the research topics of 'Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib'. Together they form a unique fingerprint.